FOXO TECHNOLOGIES INC. Operating Lease, Right-of-Use Asset, Amortization Expense
FOXO TECHNOLOGIES INC. (FOXO) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $443.11 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-15.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-04-15
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $120.39K, a 7.22% increase year-over-year.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $112.40K, a 174.94% increase year-over-year.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-06-30 was $107.39K, a 2216.89% increase year-over-year.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-03-31 was $102.93K.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $443.11K, a 180.81% increase from fiscal 2024.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $157.80K.
- FOXO TECHNOLOGIES INC. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $28.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month as first filed | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $120.39K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $232.78K derived: sum of 2 quarters · filed 2026-04-15 | $340.17K derived: sum of 3 quarters · filed 2026-04-15 | $443.11K 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $112.40K 10-Q · filed 2025-11-10 | $219.79K derived: sum of 2 quarters · filed 2025-11-10 | $322.72K 10-Q · filed 2025-11-10 | $435.00K derived: sum of 4 quarters · filed 2026-04-15 | |||
| 2025-06-30 | $107.39K 10-Q · filed 2025-08-19 | $210.32K 10-Q · filed 2025-08-19 | $322.60K derived: sum of 3 quarters · filed 2026-04-15 | $363.48K derived: sum of 4 quarters · filed 2026-04-15 | |||
| 2025-03-31 | $102.93K 10-Q/A · filed 2025-08-19 | $215.21K derived: sum of 2 quarters · filed 2026-04-15 | $256.09K derived: sum of 3 quarters · filed 2026-04-15 | $260.73K derived: sum of 4 quarters · filed 2026-04-15 | |||
| 2024-12-31 | $112.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $153.16K derived: sum of 2 quarters · filed 2026-04-15 | $157.79K derived: sum of 3 quarters · filed 2026-04-15 | $157.80K 10-K · filed 2026-04-15 | |||
| 2024-09-30 | $40.88K 10-Q · filed 2025-11-10 | $41.00K 10-Q · filed 2024-11-19 | $45.52K derived: sum of 2 quarters · filed 2025-11-10 | $45.52K 10-Q · filed 2025-11-10 | $46.00K 10-Q · filed 2024-11-19 | ||
| 2024-06-30 | $4.63K 10-Q · filed 2025-08-19 | $4.00K 10-Q · filed 2024-08-19 | $4.63K 10-Q · filed 2025-08-19 | $4.00K 10-Q · filed 2024-08-19 | |||
| 2022-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $28.00K 10-K · filed 2024-06-06 | |||||
| 2022-09-30 | $20.00K 10-Q · filed 2022-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |